Datroway (datopotamab deruxtecan-dlnk) Letter of Medical Necessity
Datroway (datopotamab deruxtecan) is a TROP2-directed antibody-drug conjugate for pretreated HR-positive, HER2-negative breast cancer and EGFR-mutated NSCLC. It is infused and billed on the medical benefit. Payers look for precise prior-line documentation and toxicity monitoring plans.
FDA-Approved Indications
- ● unresectable or metastatic HR-positive, HER2-negative breast cancer after endocrine therapy and chemotherapy
- ● locally advanced or metastatic EGFR-mutated non-small cell lung cancer after EGFR-directed therapy and platinum chemotherapy
Why Datroway Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Prior endocrine therapy and chemotherapy (breast) or EGFR TKI and platinum chemotherapy (lung) not documented
- 2. HR/HER2 or EGFR mutation status not attached
- 3. Billed under the wrong benefit or missing HCPCS code
- 4. Baseline ophthalmic exam and ILD risk assessment not documented
- 5. Preferred ADC (e.g., Trodelvy or Enhertu) required first
What to Include in a Datroway Letter of Medical Necessity
Document receptor status (HR, HER2) or EGFR mutation, each prior line with agents, dates, and progression, and the NCCN category for this setting. Include a baseline ophthalmic exam with planned eye-care prophylaxis, stomatitis prophylaxis, and ILD risk assessment, and address any prior ADC exposure.
Key clinical evidence to cite:
- ✓ TROPION-Breast01 Phase 3 trial — longer progression-free survival vs investigator-choice chemotherapy in pretreated HR+/HER2- breast cancer
- ✓ TROPION-Lung studies — objective responses in EGFR-mutated NSCLC after TKI and platinum chemotherapy
- ✓ Structured monitoring for ocular surface toxicity, stomatitis, and interstitial lung disease
Relevant guidelines:
- 📖 NCCN Breast Cancer Guidelines
- 📖 NCCN Non-Small Cell Lung Cancer Guidelines
Datroway Prior Authorization Criteria
Standard criteria across major US payers for Datroway. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior endocrine therapy and chemotherapy (breast) or EGFR TKI and platinum chemotherapy (lung) not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Datroway
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Datroway Prior Authorization FAQ
Why was my Datroway prior authorization denied?
The most common denial reasons for Datroway are: Prior endocrine therapy and chemotherapy (breast) or EGFR TKI and platinum chemotherapy (lung) not documented; HR/HER2 or EGFR mutation status not attached; Billed under the wrong benefit or missing HCPCS code; Baseline ophthalmic exam and ILD risk assessment not documented; Preferred ADC (e.g., Trodelvy or Enhertu) required first.
What should a Datroway Letter of Medical Necessity include?
Document receptor status (HR, HER2) or EGFR mutation, each prior line with agents, dates, and progression, and the NCCN category for this setting. Include a baseline ophthalmic exam with planned eye-care prophylaxis, stomatitis prophylaxis, and ILD risk assessment, and address any prior ADC exposure.
Which payers cover Datroway?
Datroway is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part B, though formulary tier and prior authorization criteria vary.